Amneal outlines 2026 guidance with 12% to 24% EPS growth target, signals acceleration in affordable medicines
Source: SeekingAlpha
2026-02-27 10:18:38 ET
More on Amneal Pharmaceuticals
- Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call Transcript
- Amneal Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Amneal Pharmaceuticals Q4 2025 Earnings Preview
- Amneal initiates nationwide settlement for opioid-related claims
Read the full article on Seeking Alpha
For further details see:
Amneal outlines 2026 guidance with 12% to 24% EPS growth target, signals acceleration in affordable medicines
Amneal Pharmaceuticals Inc. Class A
NASDAQ: AMRX
AMRX Trading
3.69% G/L:
$13.505 Last:
615,861 Volume:
$13.21 Open:
AMRX Latest News
AMRX Stock Data
$4,628,993,997
156,741,352
0.09%
93
N/A
Pharmaceuticals
Healthcare
US
Bridgewater
